US2020164021A1PendingUtilityA1
Methods for enhancing synaptogenesis and neuritogenesis
Est. expiryOct 31, 2036(~10.3 yrs left)· nominal 20-yr term from priority
A61K 38/063A61K 38/10A61K 38/07A61K 31/221A61K 31/41A61K 38/085A61K 31/15A61K 31/185A61P 25/02C07K 14/475A61K 31/198A61P 25/00A61P 27/16
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed here is a method for enhancing synaptogenesis and/or neuritogenesis, reducing neurodegeneration, and/or reducing accumulation or aggregation of Tau proteins in a subject suffering from cochlear synaptopathy or vestibular synaptopathy or a central nervous system disease or condition, comprising administering to said subject in need thereof an effective amount of 2,4-disulfonyl α-phenyl tertiary butyl nitrone (2,4-DSPBN) or a pharmaceutically acceptable salt thereof. The method may further comprise administrating N-acetylcysteine (NAC) to the subject.
Claims
exact text as granted — not AI-modified1 - 27 . (canceled)
28 . A method for reducing neurodegeneration in a subject, comprising administering to said subject in need thereof an effective amount of 2,4-disulfonyl α-phenyl tertiary butyl nitrone (2,4-DSPBN) or a pharmaceutically acceptable salt thereof.
29 . A method for reducing accumulation of Tau proteins in a subject, comprising administering to said subject in need thereof an effective amount of 2,4-disulfonyl α-phenyl tertiary butyl nitrone (2,4-DSPBN) or a pharmaceutically acceptable salt thereof.
30 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.